Hologic complements Focal; Allogene for IPO; Ga...

National health authorities, U.K.'s NICE determines Gilead's cancer cell therapy exorbitant The National Institute for Health and Care Excellence (NICE) found Gilead's cancer cell therapy, Yescarta to be clinically efficacious for treating a type of lymphoma, but no ample evidence is present to estimate the benefit...

Blueberry Therapeutics reels in USD 12.7 Million in series B funding for fungal infections. U.K.based, Blueberry Therapeutics successfully bagged a funding of USD 12.7 million in series B funding. The funding will help the company to advance its nanomedicine candidate, BB2603 for two fungal infections namely- Ath...

Personalized Medicine (also referred as Precision Medicine) is a tailored approach of deciding and predicting treatment practices based on the molecular analysis of patient’s proteins, metabolites and genetic makeup. This specific treatment approach can be considered as an extension of traditional approaches to unde...

Sarepta builds in gene therapy with $30M Lacerta deal Sarepta has dampen its enthusiasm for an ongoing gene therapy candidate. Sarepta has made a tie-up with lacerta that will add 3 more programs to 8 already existing and are ready to expand its focus beyond muscular dystrophy. Sarepta has committed to pay Lacerta ...

 Can CRISPR really fix genetic mutation in human embryos?  Team of scientists who created controversial blockbuster last year claim that they have fixed a disease-causing mutation in human embryos using gene editing technique CRISPR. Team has released fresh evidence supporting their work. Critics argued that the ev...

Idera's dermatomyositis drug missed primary endpoint in phase 2 Idera’s toll-like receptor (TLR) antagonist, IMO-8400, failed to meet its primary endpoint in a phase 2 trial carried on adults with dermatomyositis. Data has shown that the drug was meant to block TLR 7, 8 and 9 but failed to beat placebo in making a s...